MedTrace Logo

Place of Glycation in Diabetic Retinopathy

NCT05364723 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-05-06

No results posted yet for this study

Summary

1. Definition: Diabetic retinopathy is a microangiopathic complication of diabetes diabetes mellitus. Its pathophysiology includes glycation and intracellular hypoxia. Diabetic retinopathy (DR) is a microvascular complication of diabetes. It is the leading cause of It is the leading cause of blindness and visual impairment in people under the age of 60 in industrialized countries.

Chronic hyperglycemia during diabetes plays a major role in the occurrence of diabetic diabetic retinopathy by promoting protein glycation and the accumulation of glycation end products (GTPs). GTPs are a heterogeneous group of compounds resulting from non-enzymatic and irreversible reactions between reducing sugars and amine groups of biological molecules such as proteins, lipids or nucleic acids.
2. Interest: The aim of our work is to describe the mechanisms by which glycation participates in the pathophysiology of diabetic retinopathy and to discuss the use of AGEs as biomarkers in this biomarkers in this pathological context and the therapeutic means that limit the toxicity of of AGEs.

The study is designed through a retrospective and prospective observational study to establish the of glycation in the occurrence of diabetic retinopathy. It will describe the demographic demographic profiles, glycemic control, clinical and paraclinical status of patients with diabetic diabetic retinopathy and will evaluate the relationship between glycation and diabetic retinopathy as well as the factors that influence this glycation in these patients, and induce the occurrence and / or of diabetic retinopathy. The data collected will allow to improve the knowledge, the diagnosis and the treatment of diabetic diabetic retinopathy, as well as a good management of the patients who should benefit from a more individualized and individualized and adequate treatment.

Conditions

  • Descriptor

Interventions

OTHER

no intervention

Sponsors & Collaborators

  • Mohammed VI University Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-15
Primary Completion
2025-05-15
Completion
2025-05-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364723 on ClinicalTrials.gov